Straits Times Index
3,111.65 +18.85 (+0.61%) Nikkei
26,491.97 +320.72 (+1.23%) Hang Seng
21,719.06 +445.19 (+2.09%) FTSE 100
7,208.81 +188.36 (+2.68%) BTC-USD
21,452.18 +178.52 (+0.84%) CMC Crypto 200
462.12 +8.22 (+1.81%)
DiaMedica Therapeutics Inc. (DMAC)
After hours:
| Previous close | 2.2700 |
| Open | 2.3100 |
| Bid | 1.9100 x 4000 |
| Ask | 1.9100 x 1800 |
| Day's range | 1.6200 - 2.3125 |
| 52-week range | 1.6200 - 7.3400 |
| Volume | |
| Avg. volume | 47,158 |
| Market cap | 49.184M |
| Beta (5Y monthly) | 2.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5940 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.80 |
- Business Wire
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
MINNEAPOLIS, May 25, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022. Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with Dia
- Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
MINNEAPOLIS, May 04, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended March 31, 2022. DiaMedica will host a conference call on Thursday, May 5, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and first quarter financial results.
- Business Wire
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
MINNEAPOLIS, April 28, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4th. DiaMedica will host a live conference call on Thursday, May 5th at 7:00 AM Central Time to provide a business update and discuss financial results.
